Paliperidone extended release for the treatment of pediatric and adolescent patients with Tourette's disorder

OBJECTIVE: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD. METHODS: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release. RESULTS: In two cases, TD sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamuro, Kazuhiko, Makinodan, Manabu, Ota, Toyosaku, Iida, Junzo, Kishimoto, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020572/
https://www.ncbi.nlm.nih.gov/pubmed/24829608
http://dx.doi.org/10.1186/1744-859X-13-13
Descripción
Sumario:OBJECTIVE: A subgroup of patients with Tourette's disorder (TD) has symptoms refractory to haloperidol, a standard therapeutic drug for TD. METHODS: We report on three cases of pediatric and adolescent patients who were treated with paliperidone extended release. RESULTS: In two cases, TD symptoms were remarkably improved by switching from haloperidol to paliperidone extended release, and in another case, paliperidone extended release showed significant efficacy in treating TD symptoms as the first-line drug. In all cases, no significant adverse side effects were detected. CONCLUSION: Paliperidone extended release may be a strong candidate for the treatment of pediatric and adolescent patients with TD.

Ejemplares similares